Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome

Tom D. A. van Kraaij; R. my L. M. Mostard; Sofia Ramiro; Cesar Magro Checa; Christel M. P. van Dongen; Eric H. J. van Haren; Jacqueline Buijs; Robert B. M. Landewé

doi:10.12890/2020_001675

Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome

Tom D. A. van Kraaij
, R. my L. M. Mostard
, Sofia Ramiro
, Cesar Magro Checa
, Christel M. P. van Dongen
, Eric H. J. van Haren
, Jacqueline Buijs
, Robert B. M. Landewé

Affiliatie UvA

Zuyderland Medical Center
Leiden University Medical Center

Research output: Contribution to journal › Article › Academic › peer-review

19 Downloads (Pure)

Abstract

Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS.

Original language	English
Journal	European Journal of Case Reports in Internal Medicine
Volume	7
Issue number	5
DOIs	https://doi.org/10.12890/2020_001675
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.12890/2020_001675

Tocilizumab-in-severe-covid-19-pneumonia-and-concomitant-cytokine-release-syndrome.pdfFinal published version, 399 KBLicence: CC BY

Cite this

@article{bb0e44fb8eb24a32bfa7e2bb12f53131,

title = "Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome",

abstract = "Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS.",

author = "\{van Kraaij\}, \{Tom D. A.\} and Mostard, \{R. my L. M.\} and Sofia Ramiro and Checa, \{Cesar Magro\} and \{van Dongen\}, \{Christel M. P.\} and \{van Haren\}, \{Eric H. J.\} and Jacqueline Buijs and Landew{\'e}, \{Robert B. M.\}",

year = "2020",

doi = "10.12890/2020\_001675",

language = "English",

volume = "7",

journal = "European Journal of Case Reports in Internal Medicine",

issn = "2284-2594",

publisher = "SMC Media Srl",

number = "5",

}

TY - JOUR

T1 - Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome

AU - van Kraaij, Tom D. A.

AU - Mostard, R. my L. M.

AU - Ramiro, Sofia

AU - Checa, Cesar Magro

AU - van Dongen, Christel M. P.

AU - van Haren, Eric H. J.

AU - Buijs, Jacqueline

AU - Landewé, Robert B. M.

PY - 2020

Y1 - 2020

N2 - Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS.

AB - Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS.

UR - https://www.scopus.com/pages/publications/85150247260

UR - https://www.ncbi.nlm.nih.gov/pubmed/32399455

U2 - 10.12890/2020_001675

DO - 10.12890/2020_001675

M3 - Article

C2 - 32399455

SN - 2284-2594

VL - 7

JO - European Journal of Case Reports in Internal Medicine

JF - European Journal of Case Reports in Internal Medicine

IS - 5

ER -

Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this